Prevention strategies of cervical cancer in the HPV vaccine era
- 31 October 2006
- journal article
- review article
- Published by Elsevier in Gynecologic Oncology
- Vol. 103 (1), 21-24
- https://doi.org/10.1016/j.ygyno.2006.07.019
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Overview of the European and North American studies on HPV testing in primary cervical cancer screeningInternational Journal of Cancer, 2006
- Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialThe Lancet, 2006
- Humoral Immune Response Recognizes a Complex Set of Epitopes on Human Papillomavirus Type 6 L1 CapsomersJournal of Virology, 2005
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialThe Lancet Oncology, 2005
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialThe Lancet, 2004
- A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccineVaccine, 2004
- Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy womenVaccine, 2004
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineNew England Journal of Medicine, 2002